RxDoctor Payments Data

Jacqueline McDaniel

Family · New Port Richey, FLNPI 1932280799

Payments from drug & device makers

$15,498in general payments, 2019–2025

Across 341 payments — averaging $45.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$11K
  • Viiv Healthcare Company$3K
  • Merck$650
  • Theratechnologies Inc.$353
  • AbbVie$331
  • Johnson & Johnson$193
  • plus $685 from 9 others

What the payments were for

  • Speaking & faculty fees$7,12546%
  • Travel & lodging$1,0907%
  • Food & beverage$7,11446%
  • Education$1691%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,498 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$3,117
Medicare patients
14
Services billed
57

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala448$1,749,579
GenvoyaElviteg/Cob/Emtri/Tenof Alafen75$306,690
JulucaDolutegravir/Rilpivirine82$287,370
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf59$265,092
TivicayDolutegravir Sodium103$219,546
CabenuvaCabotegravir/Rilpivirine26$165,290
DescovyEmtricitabine/Tenofov Alafenam59$122,568
OdefseyEmtricitab/Rilpiviri/Tenof Ala33$112,646
TriumeqAbacavir/Dolutegravir/Lamivudi29$103,798
PrezcobixDarunavir/Cobicistat41$96,127
StribildElviteg/Cob/Emtri/Tenofo Disop19$75,758
DovatoDolutegravir Sodium/Lamivudine19$56,853
MytesiCrofelemer14$33,630
RybelsusSemaglutide14$12,760
GlyxambiEmpagliflozin/Linagliptin12$6,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy, Stribild$10,777$2,254,596601 claims
Viiv Healthcare CompanyJuluca, Tivicay, Cabenuva, Triumeq, Dovato$2,509$832,858259 claims
Janssen Products, LPSymtuza$169$265,09259 claims
Johnson & JohnsonPrezcobix$193$96,12741 claims
Napo Pharmaceuticals IncMytesi$69$33,63014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in New Port Richey

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →